Key terms

About BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BHC news

Apr 15 7:20am ET Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH) Apr 12 6:50am ET Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS) Apr 11 1:37pm ET Bausch Health Wins Patent Appeal for XIFAXAN Apr 11 1:14pm ET Bausch Health says ruling prevents FDA approval of Norwich ANDA until 2029 Apr 11 11:38am ET Bausch ‘win’ in Xifaxan case clears major hurdle ahead of spin, says Jefferies Apr 11 11:09am ET Appeals court affirms ruling in Bausch Health-Norwich patent fight Apr 11 8:40am ET Bausch Health announces ARAZLO availability through BC PharmaCare Apr 08 5:00pm ET Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues Apr 08 2:57pm ET Bausch suit creates added uncertainty on B+L spin, says TD Cowen Apr 08 10:00am ET Bausch Health falls -6.4% Apr 05 6:37pm ET Bausch Health Defends XIFAXAN® Patent Apr 05 6:19pm ET Bausch Health files patent lawsuit against Amneal Pharmaceuticals Apr 05 3:06pm ET Bausch Health call volume above normal and directionally bullish Apr 05 7:10am ET Bausch Health price target raised to $12 from $9 at RBC Capital Apr 05 6:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH) Apr 04 8:10am ET Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB) Apr 03 8:42am ET Bausch Health Canada announces public drug plan listings for UCERIS Mar 28 8:17am ET Jefferies sees more upside for Bausch Health if Xifaxan ruling positive Mar 28 8:00am ET Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT) Mar 22 7:27am ET 5 Stocks Billionaire Investor Carl Icahn is Buying Now Mar 06 8:18am ET Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR Feb 27 7:41am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), IQVIA Holdings (IQV) and Bausch Health Companies (BHC) Feb 23 9:24am ET Bausch Health price target raised to $7 from $6 at BofA Feb 23 7:20am ET Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Insulet (PODD) and Teleflex (TFX) Feb 23 7:20am ET Bausch Health Companies (BHC) Gets a Hold from RBC Capital Feb 23 5:30am ET Analysts’ Top Healthcare Picks: Bausch Health Companies (BHC), Teleflex (TFX) Feb 23 5:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC) Feb 23 5:20am ET Bausch Health Companies: Sell Rating Justified by Modest Growth Outlook and Persistent Uncertainties Feb 22 8:27am ET Bausch Health sees 2024 revenue $9.3B-$9.55B, consensus $9.02B Feb 22 8:26am ET Bausch Health reports Q4 EPS (11c), consensus $1.02 Feb 20 9:06am ET Bausch Health price target lowered to $14 from $16 at Jefferies

No recent press releases are available for BHC

BHC Financials

1-year income & revenue

Key terms

BHC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BHC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms